Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)

NCT00098839 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00098839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00098839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Pilot and Phase II Study Of Chemoimmunotherapy With Epratuzumab (IND #12034) for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2005
Completion date
April 30, 2011
Enrollment
134 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent childhood acute lymphoblastic leukemia